Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Assets (2016 - 2025)

Historic Assets for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $54.2 million.

  • Spero Therapeutics' Assets fell 5992.19% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.2 million, marking a year-over-year decrease of 5992.19%. This contributed to the annual value of $110.5 million for FY2024, which is 3939.2% down from last year.
  • As of Q3 2025, Spero Therapeutics' Assets stood at $54.2 million, which was down 5992.19% from $62.1 million recorded in Q2 2025.
  • Spero Therapeutics' 5-year Assets high stood at $182.4 million for Q4 2023, and its period low was $54.2 million during Q3 2025.
  • Its 5-year average for Assets is $117.7 million, with a median of $119.6 million in 2021.
  • Its Assets has fluctuated over the past 5 years, first surged by 6610.99% in 2023, then crashed by 5992.19% in 2025.
  • Over the past 5 years, Spero Therapeutics' Assets (Quarter) stood at $171.1 million in 2021, then fell by 27.05% to $124.8 million in 2022, then skyrocketed by 46.14% to $182.4 million in 2023, then plummeted by 39.39% to $110.5 million in 2024, then crashed by 51.0% to $54.2 million in 2025.
  • Its Assets was $54.2 million in Q3 2025, compared to $62.1 million in Q2 2025 and $77.7 million in Q1 2025.